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Abstract
Background: T-cell infiltrates may persist in muscle tissue of polymyositis (PM) and dermatomyositis (DM) patients
despite aggressive immunosuppressive treatment. Here, we investigated to what extent persistent T cells in affected
muscle were FOXP3+, a marker for regulatory T cells (Tregs), or CD244+, a marker for CD28null T cells, and whether their
presence correlated to clinical outcome. The sensitivity of CD28null T cells towards glucocorticoid and Treg-mediated
immunosuppression was also investigated.
Methods: Muscle biopsies from 16 newly diagnosed or untreated patients with PM/DM were investigated by
immunohistochemistry for expression of CD3, FOXP3 and CD244 before and after treatment with glucocorticoids and
immunosuppressive agents. For clinical evaluation, serum levels of creatine kinase, muscle performance (FI and MMT8),
disease activity (MITAX) and disability (HAQ) were measured. In vitro suppressive effects of glucocorticoids and Tregs on
T-cell activation were measured by CD69 upregulation.
Results: Before treatment, CD244+ cells were present at higher proportions compared to FOXP3+ cells in the inflamed
muscle. Following treatment, FOXP3+ cell numbers decreased while CD244+ cells persisted. Patients with impaired
muscle function (<75 % FI) post-treatment had higher levels of CD244+ cells in the follow-up biopsy compared to those
with FI >75 %. MITAX and HAQ correlated with the number of CD244+ cells post-treatment. CD4+CD28null T cells
displayed lower sensitivity towards both glucocorticoid and Treg-mediated immunosuppression in vitro compared to
their CD28+ counterparts.
Conclusions: Poor outcome in patients with myositis following immunosuppressive therapy was linked to persistence of
CD244+ (CD28null) T cells in muscle tissue, suggesting their resistance against immunosuppression. A relative loss of
regulatory T cells could also contribute to poor clinical outcome given their recently ascribed role in muscle tissue
regeneration.
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Background
Polymyositis (PM) and dermatomyositis (DM) are char-
acterized by chronic muscle weakness and inflammation
in muscle tissue leading to disability, decreased quality
of life and reduced life expectancy. Histopathologically,
these myopathies are characterized by immune cell infil-
trates, mainly T cells and macrophages in the skeletal
muscle tissue [1–3].
Conventional treatment of PM and DM is based on the
use of glucocorticoids in high doses over an extended
period of time together with additional immunosuppres-
sive agents [4]. More recently, exercise has also become an
important part of the treatment [5]. However, the treat-
ment outcome is unpredictable in the patients [4]. In some
patients, the inflammatory infiltrate in muscle tissue per-
sists despite aggressive immunosuppressive treatment and
is associated with remaining muscle weakness [6–8]. In
this context, the CD28null T cells are of particular interest
as they are long-lived and suggested to be resistant to
apoptosis [9–12]. CD28null T cells are highly differentiated
cells lacking the co-stimulatory molecule CD28, are often
clonally expanded and display proinflammatory effector
functions such as interferon gamma (IFNγ) and tumor ne-
crosis factor (TNF) production as well as cytotoxic cap-
acity and upregulation of activating receptors mostly
associated with natural killer (NK) cells [13–15]. Frequen-
cies of CD28null T-cell subsets are higher in CD8 as com-
pared to CD4 lineage, but still relatively low in healthy
individuals [16] but are increased in the elderly [17] and in
various chronic inflammatory and autoimmune conditions
[14, 18–22]. Contrary to these proinflammatory cells,
FOXP3+ regulatory T cells (Tregs) are key players in the
maintenance of peripheral tolerance by limiting T-cell acti-
vation and effector function [23, 24]. Interestingly, there is
a growing body of data indicating that tissue-resident
FOXP3+ Tregs are also instrumental for repair and tissue
regeneration, and for muscle this can be accomplished by
both direct effects on muscle precursor cells [25] and via
the growth factor amphiregulin [26]. No data in this con-
text are so far available for patients with myositis.
Recent results from our group demonstrate that
CD244 can be used as a surrogate marker to identify
CD28null T cells in the circulation and in the muscle tis-
sue of myositis patients, and also that the majority of the
muscle-infiltrating T cells in myositis patients are of the
proinflammatory CD28null phenotype [27, 28]. However,
FOXP3+ Tregs have also been described in myositis
muscle tissue [29]. Interestingly, it has been demon-
strated in peripheral blood mononuclear cells (PBMCs)
from healthy donors that CD28null T-cell proliferation
and function could only partly be suppressed by Tregs
[30]. This led to our interest towards the efficacy of
Tregs and glucocorticoids in limiting local CD28null T-
cell activation and persistence in the setting of myositis.
In the present study we have investigated the effects of
immunosuppressive treatment on CD3+ (T-cell marker),
CD244+ (CD28null T-cell marker) and FOXP3+ (regulatory
T-cell marker) cells in myositis muscle tissue, and its relation
to the short- and long-term clinical outcomes for patients with
PM and DM, as well as the in vitro immunosuppressive ef-
fects on circulating CD28null T cells. We demonstrate here
that a poor outcome following glucocorticoid therapy is linked
to persistence of CD244+ cells in muscle tissue, i.e., CD28null
T cells and a relative decrease of Tregs following such therapy.
Furthermore, CD28null T cells isolated from the circulation of
myositis patients were resistant to both glucocorticoid and
Treg-mediated immunosuppression in vitro.
Methods
Patients, treatment and healthy donors
This is an observational, prospective study including
newly diagnosed patients at the Karolinska University
Hospital with definite or probable PM or DM who gave
consent to have a re-biopsy after treatment with conven-
tional immunosuppressive treatment [31, 32]. A second
biopsy was planned after 6 months with immunosuppres-
sive treatment including prednisolone with a starting dose
of 40–60 mg/day, slowly tapering, in combination with a
disease-modifying drug according to the treating physi-
cian’s choice (azathioprine 2 mg/kg/day or methotrexate
15–20 mg/week) (Table 1). Muscle biopsies taken before
and after treatment were available from sixteen patients
(Table 1). Only those who had at least 10 CD3+ cells in
muscle-biopsy sections with a minimum of 2 CD3+ cells/
mm2 either before or after treatment (n = 14) (patients 1–
14; Table 1) were included for T cell phenotype analysis in
muscle tissue and clinical evaluation post-treatment. For
long-term clinical follow-up, all sixteen patients were in-
cluded. The patients were followed with registration of
clinical data in the SweMyoNet registry. Data from a time
point 5 to 10 years from start of treatment were included
to determine long-term outcomes.
For in vitro immunosuppression assays, PBMCs from
6 untreated myositis patients (2 DM, 4 PM; median age
63.5 (43–74) years) and 6 healthy donors (buffy coats),
all with at least 2 % CD4+ CD28null T-cell frequency
(patients, median 15.2 %, range 2.01–22.8 %; healthy do-
nors, median 5.9 %, range 2.08–14.6 %) in peripheral
blood were obtained.
Ethics, consent and permissions
All participants gave informed consent to participate in
the study, which was approved by the regional Human
Ethics Committee at Karolinska Institutet, Stockholm.
Autoantibodies (as listed in Table 1)
Patient sera were tested for antinuclear antibodies (ANA)
by indirect immunofluorescence as a routine test using
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Hep-2 KS cells and fluorescein-labeled anti-human IgG
at the Department of Clinical Immunology, Karolinska
University Hospital. Myositis-specific and -associated
autoantibodies were identified by line immunoassay
(Myositis Profile Euroline, Euroimmun, Lubeck, Germany)
by Dr. P. Charles, Kennedy Institute of Rheumatology,
London, UK [33].
Muscle biopsy specimens and immunohistochemistry
analysis
Biopsy specimens were obtained from the vastus-lateralis
or tibialis-anterior muscle by a “semi-open” technique
under local anesthesia [34, 35], before and after treatment.
The muscle biopsies were immediately frozen in isopen-
tane, chilled by liquid nitrogen, stored at –70 °C, and 7-μm
thick biopsy sections were prepared for immunohistochem-
istry. As demonstrated previously by Fasth et al., CD244
was used as a surrogate marker to detect the presence of
CD28null T cells in muscle tissue of DM and PM patients
[27]. This facilitates direct quantification of CD28null T
cells (which are highly differentiated effector T cells) and re-
duces the risk for inclusion of recently activated T cells
temporarily downregulating CD28. Therefore, in order to
quantify the total number of T cells in muscle tissue and
the fraction of CD244+ T cells, serial sections of patient
muscle biopsies were stained for CD3 and CD244 using
immunohistochemistry. To quantify the number of
Tregs, muscle biopsy sections were stained for FOXP3.
Mouse monoclonal anti-human CD3 (clone SK7; Becton
Dickinson, USA), goat anti-human CD244 (R&D Systems,
Minneapolis, MN, USA) and mouse anti-human Foxp3
(IgG1, clone 236/E7, 1; eBioscience, San Diego, CA, USA)
antibodies were used to detect the presence of CD3,
CD244 and FOXP3, respectively. Respective isotype con-
trol antibodies were irrelevant mouse IgG1 (DAKO,
Glostrup, Denmark) or goat IgG (Caltag Laboratories).
Stainings were performed as described elsewhere [28, 36].
Stained tissue sections were examined using a Polyvar II
microscope (Reichert-Jung, Vienna, Austria) and a Leica
DM RXA2 microscope (Leica Microsystems, Wetzlar,
Germany) and photographed with a Leica DC digital color
video camera 300 F (Leica Microsystems DI, Cambridge,
UK). The number of cells expressing CD244, FOXP3 and
CD3 per unit area (mm2) was assessed quantitatively using
computer-assisted image analysis. Prior to the microscopic
evaluation, slides were coded by a third person and ana-
lysis was blinded.
Clinical outcome measures
For clinical evaluation, post-treatment muscle performance
was measured by the disease-specific Functional Index (FI)
of myositis at biopsy time points [37]. Post-treatment
Table 1 Patient demography and treatment
Patient no. Diagnosis Treatment duration
at second biopsy (months)
Cumulative prednisolone
dose at second biopsy (mg)
Other immunosuppressive






1 DM 8 6005 MTX +, granular neg
2 DM 5 5210 AZA +, granular neg
3 DM 7 7875 None +, granular neg
4 DMa 10 4778 MTX +, granular anti-Ro-52, anti-Ro-60,
anti-LA
5 DM 11 7179 AZA +, granular neg
6 DM 9 8668 AZA neg anti-Ro-52
7 DMb 4 3935 None +, granular anti-Ro-52, anti-PL7
8 DMb 8 NA AZA, CsA +, granular anti-Ro-52
9 PM 6 5250 MTX +, granular and
homogenous
anti-Ro-52, anti-SRP
10 PM 12 9090 AZA +, granular neg
11 PM 11 9013 MTX, AZA NA NA
12 PMb 16 6775 AZA neg anti-Mi2
13 PMb 4 5525 CYC neg anti-Jo-1, anti-Ro-52
14 PMb 6 1360 None neg neg
15 PM 9 3702 AZA neg anti-Ro-52, anti-Ro-60
16 PM 8 8435 AZA +, granular anti-Ro-52
aAdditional diagnosis Sjögren's syndrome.
bDiagnosis probable
+ positive, ANA anti-nuclear antibodies, AZA azathioprine, CsA cyclosporine A, CYC cyclophosphamide, DM dermatomyositis, MTX methotrexate, NA not available,
neg negative, PM polymyositis
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5-year follow-up of disease activity was performed by the
Myositis Intention To Treat Activity Index (MITAX) [38]
and muscle strength was measured by Manual Muscle
Testing 8 (MMT8) [39]. Additionally, to measure limita-
tions in daily activities and disability at 5-year and 6- to
10-year follow-up, the Health Assessment Questionnaire
(HAQ) disability index was employed [40]. Detailed infor-
mation about MITAX, MMT8 and HAQ can be found on
the "Disease Activity Core Set Measures" section of the
International Myositis Assessment and Clinical Studies
Group (IMACS) webpage. (http://www.niehs.nih.gov/
research/resources/imacs/index.cfm). Serum levels of
creatine kinase (s-CK) at the time of muscle biopsy were
analyzed as a measurement of muscle damage as routine
analyses at the Department of Clinical Chemistry at
Karolinska University Hospital.
In vitro immunosuppression assay
The immunosuppressive potential of Tregs on T-cell sub-
sets was measured using BD FastImmune™ Human Regu-
latory T Cell Function Kit (BD Bioscience, USA), with a
slightly modified protocol. Glucocorticoid-mediated sup-
pression on T-cell subsets was also studied. For in vitro
assays, RPMI + 2 mM L-glutamin + 100 units/ml penicil-
lin + 100 μg/ml streptomycin + 10 μM Hepes (all from
Sigma-Aldrich) + 10 % pooled human AB serum (from
the Karolinska University Hospital Blood Center) was used
as the cell culture medium. PBMCs were stimulated with
plate-bound anti-CD3 (2.5 μg/ml, OKT-3) in U-bottomed
96-well plates. At the same time, either glucocorticoid
(2 μg/ml, Solu-Medrol®, Pfizer) or Tregs (Tregs to target
cell/PBMC ratio 1:8) were added. Tregs were isolated
from PBMCs using immunostaining with the follow-
ing anti-human antibodies: CD4-FITC, CD3-PerCp-Cy5.5
and CD25-PE (BD Bioscience). Tregs were sorted on a
MoFlow high-speed cell sorter (Beckman Coulter, USA)
as CD3+CD4+CD25high. The cell cultures were kept for
7–10 h at 37 °C, 5 % CO2, and stained with the following
anti-human antibodies: CD4-FITC, CD25-PE, CD3-
PerCP-Cy5.5; CD69-PE-Cy7; CD28-APC (BD Bioscience).
Stained cells were acquired by flow cytometry on a CyAn
(Beckman Coulter, USA) and the data were analyzed by
FlowJo software version 9.0 (Tree star Inc. Ashland,
Oregon, USA). T-cell activation, as measured by CD69 ex-
pression, was analyzed on the effector T-cell subsets di-
vided into CD4+CD28+ or CD4+CD28null T cells based
on CD28 expression. Suppression, by either glucocorticoid
or Tregs, was quantified as percentage reduction in up-
regulation of the activation marker CD69 by measuring
geometrical mean fluorescence intensity (GMFI) of sam-
ples compared to stimulated (STM) and unstimulated
(UNSTM) controls using the following formula: % sup-
pression = (GMFI of STM – GMFI of sample) × 100/
(GMFI of STM – GMFI of UNSTM).
Statistical analysis and graphing
Correlations in the study were analyzed using the two-
tailed Spearman correlation test. The Spearman correlation
coefficient (rs) was interpreted as follow for the degree of
correlation: 0–0.25 as no or very low, 0.26–0.40 as low,
0.41–0.69 as moderate, 0.70–0.89 as high, and 0.90–1.0 as
very high correlation [41]. The Mann-Whitney two-tailed
test was used to compare CD3+ cells/mm2 and CD244+
cells/mm2 between ΔFI groups and FI groups post-
treatment (FI-high and FI-low groups). For all paired com-
parisons, two-tailed Wilcoxon matched-pairs signed rank
test was used. The software program GraphPad Prism
(version 5.0 for Mac) was used for all graphing and statis-
tical analysis including linear regression analysis.
Results
Despite a good clinical response at the group level, many
patients regained less than 75 % of their muscle function
For the cohort of 16 patients (11 females, 5 males), the
median age at the time of first biopsy was 61.5 (range
41–88) years (Table 1). At the time of the repeat biopsy,
median treatment duration was 8 months (range 4–16),
with a median cumulative prednisolone dose of 6005 mg
(1360–9090 mg). Overall, the patient cohort responded
well to treatment. Out of the 14 patients included in the
T-cell phenotyping, s-CK data were available from 11
patients and FI data were available from 12 patients. s-
CK levels had decreased at follow-up, i.e., time of the
second biopsy (median before 20.0 μcat/L, after 1.9
μcat/L; p = 0.003) (Fig. 1a). Improvement in FI measure-
ment was displayed in 11 out of 12 patients. At the
group level, FI improved from 50.7 % (median) to 78.1 %
post-treatment (p = 0.005) (Fig. 1b). Eight out of 12 pa-
tients displayed more than 20 % improvement in the FI
(i.e., ΔFI).
Based on the levels of FI score post-treatment, patients
clustered into two groups: one group with FI higher than
75 % (FI-high group, range 85.8–100, n = 6) and another
with FI less than 75 % (FI-low group, range 37.5–
70.5, n = 6), and hence less good clinical response (Fig. 1b).
CD244+ cells dominate the T-cell infiltrate in inflamed
myositis muscle tissue
Muscle biopsy sections were utilized to study CD3+,
CD244+ and FOXP3+ cells in myositis muscle tissue.
Figure 2a–c depicts representative examples of CD3,
CD244 and isotype control staining. Figure 2d is a repre-
sentative staining for FOXP3 in muscle tissue of myositis
patients. Of the 14 patients analyzed, the number of
CD3+ T cells before the start of treatment ranged be-
tween 0.5–963 cells/mm2 (median 13.5) (Fig. 2e) while
the number of CD244+ cells varied between 0–666 cells/
mm2 (median 4.6) (Fig. 2e). Most areas positive for CD3
also stained positive for CD244 on consecutive sections
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(Fig. 2a and b). Both CD244+ cells/mm2 (rs = 0.92, p <
0.0001) and FOXP3+ cells/mm2 (rs = 0.89, p < 0.0001)
correlated strongly with CD3+ cells/mm2, strengthening
the data that CD244 and FOXP3 staining is T-cell spe-
cific (Fig. 2e and f). Note that even after removing the
outlier in Fig. 2e, a strong correlation was observed (rs =
0.90, p < 0.0001).
FOXP3+ cells were present in lower numbers than
CD244+ cells in myositis muscle tissue (median 1.69
FOXP3+ cells/mm2, range 0–21.3, p = 0.0002) (Fig. 2g).
When comparing the proportions (% of total T cells),
CD244+ cells (median 33.4 %, range 0–85.7 %) were
present in approximately 10-fold higher proportion com-
pared to FOXP3+ cells (median 3.4 %, range 0–71.1 %,
p = 0.01) in the myositis muscle tissue (Fig. 2h).
CD244+ cells persist post-treatment in myositis muscle
tissue, while the number of FOXP3+ cells decreases
After a median 8 months of treatment, the median T-
cell number in muscle tissue was 4.5 cells/mm2, which
was significantly lower compared to before treatment
(13.5 cells/mm2, p = 0.02) (Fig. 3a). However, the number
of CD244+ cells/mm2 did not change significantly post-
treatment (p = 0.58) (Fig. 3b). Representative staining
displaying persistence of CD244+ cells among CD3+
cells in post-treatment muscle biopsies is shown in
Fig. 3c and d. On the contrary, the number of FOXP3+
cells was lower, 0.48 cells/mm2 (median) compared to
before treatment 1.69 cells/mm2 (p = 0.01) (Fig. 3e).
The persistence of CD244+ cells led to an increase in
CD244+/CD3+ proportion from 33.3 % (median) to 51.9 %
in post-treatment muscle tissue (p = 0.02) (Fig. 3f), while
the FOXP3+/CD3+ proportion did not change (p = 0.79)
(Fig. 3g). Also at the individual patient level, a majority (9/
14) of patients displayed increases in CD244+/CD3+ pro-
portion post-treatment (Fig. 3h), while the FOXP3+/CD3+
proportion was unchanged or lower for the majority
of patients (10/14) (Fig. 3i). The relative proportion of
CD244/FOXP3 increased for 7 patients, remained un-
changed for 4 patients and decreased for 3 patients post-
treatment (Fig. 3j). These results indicate that treatment
led to a relative decrease in FOXP3/CD3 proportion com-
pared to the CD244/CD3 proportion for the majority of
patients.
Persistence of CD244+ cells in muscle tissue is linked to
relatively poor outcome following glucocorticoid therapy
Next, we investigated whether clinical response in pa-
tients was associated with the number and phenotype of
T-cell subsets in the muscle biopsies. When patients
were compared based on the FI improvement (ΔFI), the
group with ΔFI ≤20 % contained significantly higher
number of both CD3+ cells/mm2 (median 254.4 versus
6.1, p = 0.004) (Fig. 4a) and CD244+ cells/mm2 (median
89.5 versus 2.3, p = 0.004) (Fig. 4b) before treatment than
the group with ΔFI >20 %. Additionally, patients in the
FI-low group post-treatment (Fig. 1b) were found to dis-
play higher levels of CD244+ cells (median 13.8 cells/
mm2, p = 0.01) in post-treatment muscle biopsies com-
pared to those in the FI-high group (median 0.8 cell/
mm2) (Fig. 4c). CD244+ cells/mm2 in post-treatment
muscle biopsies also displayed an almost significant
moderate negative correlation with FI after treatment
(rs = –0.53, p = 0.07) (Fig. 4d).
CD244+ cells/mm2 in post-treatment muscle biopsies
were also associated with various clinical parameters at
long-term follow-up in patients. Post-treatment CD244+
cells/mm2 correlated significantly with patient disease activ-
ity MITAX at 5-year follow-up (rs = 0.64, p = 0.03) (Fig. 4e),
and also displayed negative correlation with muscle
strength in patients at 5-year follow-up, measured by
MMT8 (rs =–0.66, p = 0.05) (Fig. 4f). The patient disability
measured by HAQ score showed positive correlation at 5-
year follow-up (rs = 0.59, p = 0.05, n = 11), and at 6- to
10-year follow-up (rs = 0.67, p = 0.02) (Fig. 4g). In
addition to correlations, CD244+ cells/mm2 post-treatment
a b
Fig. 1 Clinical evaluation of patients before and after immunosuppressive treatment. Serum creatine kinase (CK) levels decreased for all patients
post-treatment (a). At the group level, Functional Index (FI) increased from 50.7 % (median) to 78.1 % post-treatment (n = 12) (b). Based on FI
score post-treatment, patients clustered into two groups: one group with FI higher than 75 % (FI-high group, n = 6) and another with FI less than
75 % (FI-low group, n = 6) (b)






Fig. 2 (See legend on next page.)
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also displayed almost significant linear regression with FI
post-treatment (Fig. 4d) and MITAX at 5 years (Fig. 4e)
and significant linear regression with MMT8 at 5 years
(Fig. 4f).
CD4+CD28null T-cell subset display resistance to
glucocorticoid and Treg-mediated immunosuppression in
vitro
We have previously demonstrated that the majority of
CD244 expressing T cells display a CD28null phenotype
in the circulation of myositis patients. Here, a flow
cytometry-based in vitro immunosuppression assay was
used to evaluate suppressive effects of glucocorticoids
and Tregs on activation-induced CD69 upregulation on
the reciprocal CD28null and CD28+ T-cell subsets.
Representative flow cytometry histograms depicting
glucocorticoid-mediated suppression of CD4+CD28+ and
CD4+CD28null T-cell subsets in myositis patients are
shown in Fig. 5a and b, respectively. As shown in the exam-
ples and in the summary graph (Fig. 5c), CD4+CD28null T
cells were less sensitive towards glucocorticoid-mediated
suppression compared to their CD28+ counterparts in
myositis patients (median suppression: 46.8 % versus
68.5 %, n = 6). Also, in healthy donors, CD4+CD28null T
cells displayed a lower sensitivity towards glucocorticoid-
mediated suppression than their CD28+ counterparts (me-
dian suppression: 51.6 % versus 80.7 %, n = 6) (Fig. 5d).
Treg-mediated in vitro immunosuppression assay could
only be performed in healthy donors since Tregs are a rare
T-cell subset requiring large sample volumes for their iso-
lation. To sort live Tregs, CD3+CD4+CD25high T cells
were selected as Tregs (Fig. 5e). In the suppression assay,
CD4+CD28null T cells were found to be less sensitive to
Treg-mediated suppression compared with their CD28+
counterparts (median suppression: 18 % versus 57.2 %)
(Fig. 5f). No clear trend could be observed in CD8+ com-
partment with regard to either glucocorticoid or Treg im-
munosuppression (data not shown).
Discussion
Despite high doses of glucocorticoids and other im-
munosuppressive drugs, immune infiltrates (with signifi-
cant proportion of T cells) often persist in the muscle
tissue of patients with PM and DM. In this study, we
could demonstrate that CD244+ cells (a validated surro-
gate marker for CD28null T cells in myositis muscle
tissue) dominate the T-cell infiltrates over FOXP3+ cells
(a marker for regulatory T cells) in inflamed myositis
muscle tissue. After treatment, CD244+ cells were found
to be unchanged, while the number of FOXP3+ cells de-
clined, leading to a relative increase in the proportion of
CD244+ cells over FOXP3+ cells. Interestingly, patients
with higher number of CD244+ cells in muscle tissue at
baseline displayed poorer clinical improvement. Further-
more, the higher number of CD244+ cells in the post-
treatment biopsies also correlated with a poor clinical
response, both in the short- and long-term perspective.
Using in vitro assays, we could further demonstrate that
both glucocorticoids and CD4+CD25high Tregs are less
capable of suppressing CD4+CD28null T cells compared
to their CD28+ counterparts, emphasizing the treatment-
resistant nature of this T-cell phenotype.
CD28null T cells phenotypically belong to a highly dif-
ferentiated effector memory T-cell subset with oligoclonal
expansions and devoted effector functions [14, 42]. A high
frequency of CD28null T cells in the circulation and in the
inflamed muscle of PM, DM and inclusion body myositis
(IBM) has previously been reported from our group [27,
28]. We have demonstrated that a majority of CD28null T
cells (89 % of the CD4+CD28null and 98 % of the CD8
+CD28null T cells) in the circulation of patients with
myositis stained positive for CD244 and strong correla-
tions were observed between CD244+ cells expressing
CD3+ and CD28null T-cell subsets [27]. Also, using a
triple immunofluorescence technique, CD244+ cells in
myositis muscle tissue stained mostly positive for CD3;
therefore these cells were considered CD28null T cells
and not NK cells [27]. The presence of common dominant
TCR Vβ amongst circulating CD28null T cells and also in
muscle tissue of inclusion body myositis, as demonstrated
previously by our group, further strengthen the domin-
ance of CD28null T cells in myositis muscle tissue [28].
Such oligoclonally expanded CD28null T cells in myositis
patients also retain their proinflammatory effector func-
tions and are not functionally exhausted [28]. Hence,
CD244 was used as a surrogate marker for CD28null T
cells in muscle tissue in the current study, even though
CD244 expression could tentatively also be expected on
gamma/delta T cells and some CD3+CD8+CD28+ T cells.
Our results demonstrate that persistence of CD244+ cells
(i.e., mainly CD28null T cells) may have a negative effect
on muscle fiber function and muscle performance.
(See figure on previous page.)
Fig. 2 Expression of CD244 (CD28null) and FOXP3 among T-cell infiltrates in muscle tissue of myositis patients. Immunohistochemistry of muscle
tissue obtained from the patients before the start of immunosuppressive treatment are shown with representative staining of CD3 (a), CD244 (b),
isotype control for CD244 (c) and FOXP3 (d). Both CD244+ cells/mm2 (95 % CI = 0.75 to 0.97) (e) and FOXP3+ cells/mm2 (95 % CI = 0.66 to 0.96)
(f) strongly correlated with CD3+ cells/mm2. The number of FOXP3+ cells was significantly lower than CD244+ cells in myositis muscle tissue (g).
When compared to total CD3+ cells, CD244+ cells were present in approximately 10-fold higher proportion compared with FOXP3+ in the
myositis muscle tissue (h). *p < 0.05, ***p < 0.001. CI confidence interval, rs Spearman correlation coefficient










Fig. 3 (See legend on next page.)
Pandya et al. Arthritis Research & Therapy  (2016) 18:80 Page 8 of 14
The CD28null T cells can contribute both directly and in-
directly towards muscle tissue damage. In comparison with
conventional CD28+ T cells, CD28null cells of both CD4
and CD8 lineage are hypersensitive to stimulation and can
release large amounts of IFNγ and TNF [14, 28, 43]. Excess
amount of these cytokines may impair the muscle repair
process by shifting the balance towards M1 macrophages,
inducing a state of chronic inflammation [44]. In addition,
CD28null T cells of both CD4 and CD8 origin can directly
kill muscle cells in their proximity by secreting granzyme B
and perforin [45]. Expression of activating NK receptor
could lower the T-cell activation threshold, which could
further predispose these cells to become autoreactive [15].
The presence of FOXP3+ cells (referred as regulatory
T cells) in muscle tissue of untreated myositis patients
has also been reported previously [29]. The numbers
and frequencies of FOXP3 cells found in our cohort are
similar with findings in the report by Waschbisch et al.
[29]. However, this is the first study which investigates
the frequencies FOXP3+ in relation to the CD244+ cells
and how their relative proportion is affected in myositis
muscle tissue by immunosuppressive treatment. Similar
to our previous study in rheumatoid arthritis, where
intra-articular glucocorticoid treatment decreased both
the number and the frequency of FOXP3+ Tregs in syn-
ovial tissue [36], we observed a decrease in the number
of FOXP3+ cells in myositis muscle tissue upon
glucocorticoid-based immunosuppresive treatment. This
may have functional consequences since FOXP3+ Tregs
have recently been demonstrated to contribute to
muscle repair and regeneration in mice [25, 26]. To-
gether, the reduced number of FOXP3+ Tregs and the
higher number of muscle-infiltrating CD28null T cells
could impair the muscle homeostasis and repair process,
leading to chronic inflammation and muscle damage.
Glucocorticoids not only interfere with signaling path-
ways related to immune activation but are also at high
doses capable of inducing apoptosis in immune cells, in-
cluding T cells [46, 47]. Other immunosuppressive drugs
commonly used in combination with glucocorticoids
such as methotrexate, azathioprine, cyclophosphamide,
and cyclosporine block the proliferative properties of T
cells and other immune cells [48]. Of note, CD28null T
cells are reported to be long-lived, resistant to apoptosis
in vivo [9–11], and also display properties of replicative
senescence [49–51]. The unusual in vivo survival and
resistance to apoptosis in CD28null T cells is mediated
by the anti-apoptotic protein Bcl-2 [9] and also by
proteasome-mediated reduction in pro-apoptotic mole-
cules such as Bim [12].
Of note, studies in the animal model of experimental
autoimmune encephalomyelitis have demonstrated that
the density of membrane-bound glucocorticoid receptors
(GCRs) on T cells is critical for apoptosis induction, and
T cells with a higher density of GCR expression are
more susceptible to glucocorticoid-mediated apoptosis
compared to those with a lower density of GCR expres-
sion [52]. Interestingly, a recent study showed a signifi-
cant loss of GCR expression in CD28null T cells in
patients with chronic obstructive pulmonary disease
(COPD) as well as in healthy controls [53]. Hence, it is
possible that CD28null T cells can escape the apoptotic
effects of high doses of glucocorticoids as well as anti-
proliferative effects of concomitant immunosuppressive
drugs, leading to their persistence in muscle tissue of pa-
tients with myositis.
CD28null T cells proliferate poorly in in-vitro conditions
due to their replicating senescent properties [49–51], and
we have also demonstrated this in the setting of myositis
[27]. Therefore, we chose to study the effect of CD25high
Tregs on T cell activation in vitro, instead of previously
used approaches to study proliferation [30]. Activation
can be measured by upregulation of early T-cell activation
markers such as CD40L and CD69. However, CD40L is
not adequately expressed on CD28null T cells [54]; there-
fore, we focused on CD69, after having validated that
CD69 upregulation occurs on CD28null T cells in both
the CD4+ and CD8+ compartment. In addition to
CD4+CD28null T cells being less sensitive to Tregs, we re-
port that CD4+CD28null T cells are also less sensitive to
glucocorticoid-mediated suppression in vitro. The reduced
sensitivity to suppression in CD28null T cells could be
due to distinct signaling mechanism in these cells, e.g.,
NK-related receptors on CD28null T cells could poten-
tially enhance or modulate their activation and function
leading to a different mode of suppression [15].
There are some limitations with the present study.
The cohort is small, due to PM/DM being rare disorders
(See figure on previous page.)
Fig. 3 Effects of immunosuppressive treatment on CD244 (CD28null) and FOXP3 expressing cells in muscle tissue. Lower number of T cells (CD3+
cells) was seen in post-treatment muscle tissue compare to muscle tissue obtained before treatment (a) while the number of CD244+ cell/mm2
did not change significantly post-treatment (b). Representative staining displaying remaining CD3+ cells in muscle tissue obtained post-treatment
(c) and persistence of CD244+ cells among CD3+ T cells in the consecutive muscle biopsy section are shown (d). The number of FOXP3+ cells
was lower post-treatment in comparison with before treatment (e). The CD244/CD3 proportion increased in post-treatment muscle tissue (f) while
the FOXP3/CD3 proportion did not change significantly (g). At the individual patient level, a majority (9/14) of patients displayed increases in
CD244/CD3 proportion post-treatment (h) while the FOXP3/CD3 proportion was unchanged or lower for the majority of patients (10/14) (i). The
relative proportion of CD244/FOXP3 increased for 7, remained unchanged for 4 and decreased for 3 patients post-treatment (j). *p < 0.05.
ns non-significant







Fig. 4 Correlation of the clinical response with the persistence of CD244+ cells in muscle tissue. Patients with low Functional Index (FI) improvement
(ΔFI ≤20 %, n = 4) had significantly higher number of CD3+ cells/mm2 (a) and CD244+ cells/mm2 (b) before treatment, compared to the patient
group with high FI improvement (ΔFI >20 %, n = 8). Patients in the FI-low group (FI <75 %) post-treatment had higher levels of CD244+ (CD28null)
T cells in post-treatment muscle biopsies compared to those in the FI-high group (FI >75 %) (c). CD244+/mm2 in post-treatment muscle biopsies
displayed negative correlation with FI after treatment (95 % CI = –0.85 to 0.08) (d). CD244+ cells/mm2 post-treatment correlated significantly with
Myositis Intention To Treat Activity Index (MITAX) at 5-year follow-up (95 % CI = 0.05 to 0.90) (e). CD244+ cells/mm2 post-treatment displayed negative
correlation with Manual Muscle Testing 8 (MMT8) at 5-year follow-up (f), and significant correlation with Health Assessment Questionnaire (HAQ) score
at 6- to 10-year follow-up (95 % CI = 0.14 to 0.90) (g). β values indicates the slope for linear regression and p value indicates if the slope is significantly
non-zero. *p < 0.05; **p < 0.01. CI confidence interval, rs Spearman correlation coefficient




Fig. 5 (See legend on next page.)
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and due to the invasive procedure with repeated muscle
biopsies. There is also clinical heterogeneity, e.g., one pa-
tient had anti-SRP antibodies, although without signs of
necrotizing myopathy. One patient also had Sjögren’s
syndrome, but her biopsy was compatible with PM and
thus her Sjögren was determined as secondary. The
group of patients is also heterogenous regarding treat-
ment at time of the second biopsy. In this observational
study the patients received similar starting doses of
prednisolone combined with a disease-modifying drug,
and a repeat muscle biopsy was planned at 6 months
follow-up, but due to issues unrelated to the effect of
treatment the median duration between start of treat-
ment and repeat biopsy was between 4 and 12 months.
It is therefore possible that differences in the total dose
of steroids at the time of repeat biopsy may have affected
our results; however, there was no correlation between
cumulative dose of prednisolone or treatment duration
with the level of CD3+ T cells or CD244+ T cells or
FOXP3+ T cells in the second biopsy, so we regard this
effect as minor.
Furthermore, long-term clinical data were not avail-
able for all patients leading to limitations in statistical
analyses. To curtail such limitations, we have pooled the
data from PM and DM. Although, we are aware of sub-
type differences, both subtypes have patients with high
frequencies of CD244+/CD28null T cells in the circula-
tion and in the muscle tissue, and these facets were im-
portant inclusion criteria in our study. The pooling of
data may provide insight into common pathogenic
mechanisms in different subtypes of disease. Our current
study focused on patients with T-cell infiltrates in
muscle and elevated frequencies of CD28null T cells in
the circulation, a feature not shared by all myositis pa-
tients. Nevertheless, inflammation and T cells persist in
a group of patients after months of immunosuppressive
treatment (Fig. 3a). Therefore, the results in this study
are particularly relevant in the context of myositis pa-
tients with persistent immune cell infiltrate.
A clinical response following treatment was supported
by decreased serum levels of creatine kinase and im-
proved FI score at the group level; however, the func-
tional improvement was partial. Patients with relatively
poor response (FI <75 %) had a significantly higher
number of CD244+ cells in post-treatment muscle biop-
sies compared to patients in the FI-high group. A high
number of CD244+ cells/area after approximately
8 months with immunosuppressive treatment correlated
with both short-term and long term (5–10 years) clinical
outcomes. These findings imply a clinical value for a re-
peated muscle biopsy after 6–8 months of immunosup-
pressive treatment and that patients with persistent T
cell and CD244+ cells in muscle tissue may require
novel treatment strategies.
Conclusions
We have demonstrated that the current treatment re-
gime based on high doses of glucocorticoids in combin-
ation with conventional immunosuppressive agents is
insufficient to eliminate CD3+ and CD244+ cells (focusing
on the subgroup of myositis patients displaying such cells).
We found that poor outcome from the immunosuppres-
sive therapy is linked to persistence of CD244+ cells in
muscle tissue in a subset of patients. These CD244+ cells
are likely CD28null T cells and immunosuppression resist-
ant, especially the CD4+CD28null T cells. Future studies
are needed to investigate the precise phenotype of muscle-
infiltrating CD244+ cells. Nevertheless, these findings pro-
vide mechanistic insight into the inefficacy of the current
treatment approach and directions for novel and im-
proved therapies.
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